Successes and challenges in clinical gene therapy.

Successes and challenges in clinical gene therapy.
复制标题

DOI:
10.1038/s41434-023-00390-5
复制
发表时间:
2023-11
期刊:
影响因子:
5.1
通讯作者:
--
中科院分区:
医学3区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

尽管在过去的三十年里,该领域经历了起起落落,但基因治疗科学仍在继续发展,并为越来越多的疾病提供了持久的治疗方法。有积极的临床试验接近各种不同器官系统的遗传和获得性疾病。方法包括对血液干细胞(HSC)、T淋巴细胞和其他免疫细胞进行体外修饰,以及通过局部或全身给药将基因或基因编辑试剂在体内递送到相关靶细胞。在这篇文章中,我们强调了基因治疗在三个高活性领域的成功和持续的挑战:通过靶向造血干细胞的遗传性血细胞疾病,使用嵌合抗原受体基因修饰的免疫效应细胞的恶性疾病,以及使用腺相关病毒(AAV)载体在体内给药的眼科、神经和凝血疾病。近年来,这些疾病中的许多已经有了真正的治疗方法,其持续的临床效益超过了其他医学方法。这些治疗方法中的每一种都面临着持续的挑战,即一次性成本高,以及按照药理学标准制造治疗剂(生物病毒和细胞产品)的复杂性。需要新的报销模式,以使有需要的患者广泛获得这些创新治疗。
Despite the ups and downs in the field over three decades, the science of gene therapy has continued to advance and provide enduring treatments for increasing number of diseases. There are active clinical trials approaching a variety of inherited and acquired disorders of different organ systems. Approaches include ex vivo modification of hematologic stem cells (HSC), T lymphocytes and other immune cells, as well as in vivo delivery of genes or gene editing reagents to the relevant target cells by either local or systemic administration. In this article, we highlight success and ongoing challenges in three areas of high activity in gene therapy: inherited blood cell diseases by targeting hematopoietic stem cells, malignant disorders using immune effector cells genetically modified with chimeric antigen receptors, and ophthalmologic, neurologic, and coagulation disorders using in vivo administration of adeno-associated virus (AAV) vectors. In recent years, there have been true cures for many of these diseases, with sustained clinical benefit that exceed those from other medical approaches. Each of these treatments faces ongoing challenges, namely their high one-time costs and the complexity of manufacturing the therapeutic agents, which are biological viruses and cell products, at pharmacologic standards of quality and consistency. New models of reimbursement are needed to make these innovative treatments widely available to patients in need.
DOI: 10.1377/hlthaff.2021.01742
发表时间: 2022-04-01
期刊: HEALTH AFFAIRS
影响因子: 9.7
作者:
Dusetzina, Stacie B.;Huskamp, Haiden A.;Keating, Nancy L.
通讯作者: Keating, Nancy L.
DOI: 10.1371/journal.pmed.0030136
发表时间: 2006-04
期刊: PLOS MEDICINE
影响因子: 15.8
作者:
Chokshi, Dave A.
通讯作者: Chokshi, Dave A.
DOI: 10.1200/jco.2015.62.0468
发表时间: 2016-01-20
影响因子: 45.3
作者:
Yabroff, K. Robin;Dowling, Emily C.;Ekwueme, Donatus U.
通讯作者: Ekwueme, Donatus U.
DOI: 10.1038/nbt0506-509
发表时间: 2006-05-01
影响因子: 46.9
作者:
Edwards, M;Murray, F;Yu, R
通讯作者: Yu, R
DOI: 10.1073/pnas.1715368115
发表时间: 2018-03-06
影响因子: 11.1
作者:
Galkina Cleary E;Beierlein JM;Khanuja NS;McNamee LM;Ledley FD
通讯作者: Ledley FD